+ All Categories
Home > Documents > Tuesday, 26th May. Time zone - CST. · 10:00 AM 09:00 AM Wednesday, 27th May. Time zone - CST....

Tuesday, 26th May. Time zone - CST. · 10:00 AM 09:00 AM Wednesday, 27th May. Time zone - CST....

Date post: 05-Jul-2020
Category:
Upload: others
View: 0 times
Download: 0 times
Share this document with a friend
2
10:00 AM 09:00 AM Tuesday, 26 th May. Time zone - CST. Virtual Event Opens 08:50 AM 08:30 AM Welcome Speech Foundation Medicine, Inc. China-US IO Collaboration Panel Co-Chaired by: Guillaume Vignon, SVP, Business Development, BeiGene Ltd. Helen Chen, Greater China Managing Partner & Head of China Life Sciences, L.E.K. Consulting Panelists: Greg Scott, Founder & CEO, ChinaBio Group Ji Li, Venture Partner, Lilly Asia Ventures Stella Xu, Managing Director, Quan Capital Yuwen Liu, Founding Partner, BOHE Angel Fund Industry Roundtable Co-Chaired by: Axel Hoos, SVP, Therapeutic Area Head of Oncology R&D, GlaxoSmithKline Bibhash Mukhopadhyay, Principal, New Enterprise Associates (NEA) Panelists: Andrew Allen, Co-Founder, President & CEO, Gritstone Oncology Dennis Purcell, Founder, Aisling Capital LLC Miro Venturi, SVP, Head of BioPharma, Foundation Medicine, Inc. Peter Thompson, Partner, OrbiMed Advisors LLC Roberto De Ponti, Head of Corporate New Venture & Strategic Investments, Helsinn Investment Fund 11:20 AM Dealmakers: Pharma-Bio M&A and Partnering Panel Co-Chaired by: Michael Margolis, Co-Head of Healthcare Investment Banking, Oppenheimer & Co. Inc. Stefan Loren, Managing Director Healthcare Investment Banking, Oppenheimer & Co. Inc. Panelists: Chris DeRespino, Executive Director, BD, Amgen, Inc. Chris Sheldon, VP & Head of Oncology BD&L, AstraZeneca John Adamou, VP, Business Development, BeiGene Ltd. Niels Emmerich, VP, Global Head Search & Evaluation, AbbVie, Inc. Patrick Tricoli, CEO, Nanobiotix Corp. Rachael Lester, Vice President Corporate Development, Harpoon Therapeutics, Inc. 12:20 PM Development Strategies Panel Co-Chaired by: Matthias Müllenbeck, Executive Director & Head Global Licensing & BD Enabling Technologies, Merck KGaA Peter Sandor, SVP, PFL Oncology, Astellas Pharma, Inc. Panelists: Alex Zhavoronkov, Founder & CEO, Insilico Medicine, Inc. David Fabrizio, VP of Translational Strategy, Foundation Medicine, Inc. Esteban Pombo-Villar, CEO, TargImmune Therapeutics AG Jennifer Harris, Vice President, Clinical Development, Oncology and Global Head, Immuno-Oncology, Syneos Health, LLC 20-Minute Big Pharma Corporate Partnering Presentation 1:20 PM 1:40 PM Silver Sponsors: Supported by: 11:00 AM DealMaking in the time of the pandemic: An interview with Nigel Sheail, Global Head of M&A and BD&L, Novartis International AG, interviewed by Jeffrey Bockman, EVP, Oncology Practice Head of Cello Health BioConsulting, previously Defined Health End of Sachs Virtual Conference (Day One)
Transcript
Page 1: Tuesday, 26th May. Time zone - CST. · 10:00 AM 09:00 AM Wednesday, 27th May. Time zone - CST. Second Day of Virtual Event 08:50 AM 08:30 AM Welcome Speech Phio Pharmaceuticals Corp.

10:00 AM

09:00 AM

Tuesday, 26th May. Time zone - CST.

Virtual Event Opens

08:50 AM

08:30 AM

Welcome Speech

Foundation Medicine, Inc.

China-US IO Collaboration PanelCo-Chaired by:Guillaume Vignon, SVP, Business Development, BeiGene Ltd.Helen Chen, Greater China Managing Partner & Head of China Life Sciences, L.E.K. ConsultingPanelists:Greg Scott, Founder & CEO, ChinaBio GroupJi Li, Venture Partner, Lilly Asia Ventures Stella Xu, Managing Director, Quan CapitalYuwen Liu, Founding Partner, BOHE Angel Fund

Industry RoundtableCo-Chaired by:Axel Hoos, SVP, Therapeutic Area Head of Oncology R&D, GlaxoSmithKlineBibhash Mukhopadhyay, Principal, New Enterprise Associates (NEA)Panelists:Andrew Allen, Co-Founder, President & CEO, Gritstone OncologyDennis Purcell, Founder, Aisling Capital LLCMiro Venturi, SVP, Head of BioPharma, Foundation Medicine, Inc.Peter Thompson, Partner, OrbiMed Advisors LLCRoberto De Ponti, Head of Corporate New Venture & Strategic Investments, Helsinn Investment Fund

11:20 AM

Dealmakers: Pharma-Bio M&A and Partnering PanelCo-Chaired by:Michael Margolis, Co-Head of Healthcare Investment Banking, Oppenheimer & Co. Inc.Stefan Loren, Managing Director Healthcare Investment Banking, Oppenheimer & Co. Inc. Panelists:Chris DeRespino, Executive Director, BD, Amgen, Inc.Chris Sheldon, VP & Head of Oncology BD&L, AstraZenecaJohn Adamou, VP, Business Development, BeiGene Ltd.Niels Emmerich, VP, Global Head Search & Evaluation, AbbVie, Inc.Patrick Tricoli, CEO, Nanobiotix Corp.Rachael Lester, Vice President Corporate Development, Harpoon Therapeutics, Inc.

12:20 PM

Development Strategies PanelCo-Chaired by:Matthias Müllenbeck, Executive Director & Head Global Licensing & BD Enabling Technologies, Merck KGaAPeter Sandor, SVP, PFL Oncology, Astellas Pharma, Inc.Panelists:Alex Zhavoronkov, Founder & CEO, Insilico Medicine, Inc.David Fabrizio, VP of Translational Strategy, Foundation Medicine, Inc.Esteban Pombo-Villar, CEO, TargImmune Therapeutics AGJennifer Harris, Vice President, Clinical Development, Oncology and Global Head, Immuno-Oncology, Syneos Health, LLC

20-Minute Big Pharma Corporate Partnering Presentation

1:20 PM

1:40 PM

Silver Sponsors: Supported by:

11:00 AM DealMaking in the time of the pandemic: An interview with Nigel Sheail, Global Head of M&A and BD&L, Novartis International AG, interviewed by Je�rey Bockman, EVP, Oncology Practice Head of Cello Health BioConsulting, previously De�ned Health

End of Sachs Virtual Conference (Day One)

Page 2: Tuesday, 26th May. Time zone - CST. · 10:00 AM 09:00 AM Wednesday, 27th May. Time zone - CST. Second Day of Virtual Event 08:50 AM 08:30 AM Welcome Speech Phio Pharmaceuticals Corp.

10:00 AM

09:00 AM

Wednesday, 27th May. Time zone - CST.

Second Day of Virtual Event

08:50 AM

08:30 AM

Welcome Speech

Phio Pharmaceuticals Corp.

Latest Trends in C&G Therapeutics I: Focusing on CAR-T, TCRS & TIL PanelCo-Chaired by:Gregory Frost, Managing Director, F1BioVentures LLCMichael Rice, Principal, Head of Advanced Therapeutics, Cello Health BioConsulting, previously De�ned HealthPanelists:Arthur Stril, VP, Corporate Development, Cellectis S.A.Helen Tayton-Martin, Chief Business O�cer, AdaptimmuneJohn Delyani, VP, Corporate & BD, Tmunity TherapeuticsThomas Shrader, Equity Research Analyst, BTIG, LLC

Latest Trends in C&G Therapeutics II: Focusing on Cancer Vaccines, Neo Antigens & Other Modalities PanelCo-Chaired by:Ben Burnett, Biotech Equity Analyst, Stifel Financial Corp.Paul Rennert, President & CSO, Aleta BiotherapeuticsPanelists:Heinz Lubenau, Co-Founder & CEO, VAXIMM GmbHPer Hellsund, President & CEO, Cybrexa Therapeutics, Inc.Sebastien Petitet, CCO, Brenus PharmaSteven Kelly, President & CEO, Carisma Therapeutics, Inc.

11:00 AM

Early Stage Innovation & Investment PanelCo-Chaired by:Kuldeep Neote, VP External Innovation, Eli Lilly and CompanyLee Greenberger, CSO, The Leukemia & Lymphoma SocietyPanelists:Hilary Hehman, Associate Vice President, Business Development, Fred Hutchinson Cancer Research CenterKate Strayer-Benton, Sr. Director of BD, Dana-Farber Cancer InstituteMeredith Fisher, Partner, Partners HealthCare InnovationRobert Radinsky, VP, Scienti�c Innovation, Oncology, Johnson & Johnson Innovation LLCRyan Schoenfeld, VP, Scienti�c Research, The Mark Foundation for Cancer Research

12:00 PM

Investor Panel Co-Chaired by:Brad Loncar, CEO, Loncar Investments, LLCSteven Dickman, CEO, CBT AdvisorsPanelists:Bibhash Mukhopadhyay, Principal, New Enterprise Associates (NEA)Michelle Doig, Partner, Omega FundsShinichiro Fuse, Managing Director, MPM Capital, Inc.Thilo Schroeder, Partner, Nextech Invest Ltd.Vanessa Lucey, Director, Head CRI Venture Fund and Clinical Accelerator, Cancer Research Institute

20-Minute Biotech Presentations

1:00 PM

Closing Speech

1:30 PM

1:20 PM

End of Sachs IOIF Forum

Silver Sponsors: Supported by:


Recommended